Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dexamethasone | 3 | 2025 | 274 | 2.410 |
Why?
|
| Seizures, Febrile | 2 | 2025 | 31 | 1.790 |
Why?
|
| Encephalitis | 3 | 2024 | 118 | 1.740 |
Why?
|
| Status Epilepticus | 2 | 2025 | 157 | 1.560 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 3 | 2025 | 35 | 1.220 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 8 | 0.940 |
Why?
|
| Drug Resistant Epilepsy | 2 | 2025 | 235 | 0.930 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2025 | 55 | 0.890 |
Why?
|
| Clinical Protocols | 1 | 2025 | 239 | 0.850 |
Why?
|
| Microglia | 1 | 2025 | 138 | 0.840 |
Why?
|
| Myelitis | 1 | 2023 | 15 | 0.800 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 33 | 0.780 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 305 | 0.760 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 543 | 0.710 |
Why?
|
| Injections, Spinal | 3 | 2025 | 136 | 0.670 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 69 | 0.670 |
Why?
|
| Brain Diseases | 1 | 2023 | 307 | 0.660 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 558 | 0.660 |
Why?
|
| Immunotherapy | 2 | 2025 | 748 | 0.650 |
Why?
|
| Pneumonia | 2 | 2017 | 333 | 0.530 |
Why?
|
| Intensive Care Units | 5 | 2025 | 524 | 0.510 |
Why?
|
| Autoantibodies | 3 | 2024 | 458 | 0.500 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 247 | 0.450 |
Why?
|
| Hashimoto Disease | 2 | 2024 | 29 | 0.420 |
Why?
|
| Child | 15 | 2025 | 25756 | 0.410 |
Why?
|
| Neurodevelopmental Disorders | 3 | 2023 | 553 | 0.370 |
Why?
|
| Multiple Sclerosis | 2 | 2025 | 382 | 0.350 |
Why?
|
| Down Syndrome | 2 | 2024 | 232 | 0.330 |
Why?
|
| Syndrome | 2 | 2023 | 1173 | 0.330 |
Why?
|
| Humans | 25 | 2025 | 131930 | 0.300 |
Why?
|
| Ethanol | 3 | 2015 | 168 | 0.300 |
Why?
|
| Child, Preschool | 8 | 2025 | 14715 | 0.290 |
Why?
|
| Male | 17 | 2025 | 64846 | 0.280 |
Why?
|
| Adolescent | 10 | 2025 | 20524 | 0.280 |
Why?
|
| Retrospective Studies | 9 | 2025 | 17345 | 0.250 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2025 | 2 | 0.240 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2025 | 7 | 0.240 |
Why?
|
| Confusion | 1 | 2025 | 17 | 0.240 |
Why?
|
| Rhizomucor | 1 | 2025 | 5 | 0.230 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2025 | 14 | 0.230 |
Why?
|
| Stroke | 2 | 2025 | 1081 | 0.230 |
Why?
|
| Mucormycosis | 1 | 2025 | 32 | 0.230 |
Why?
|
| Corticosterone | 2 | 2015 | 60 | 0.220 |
Why?
|
| Checklist | 1 | 2025 | 95 | 0.220 |
Why?
|
| Delirium | 1 | 2025 | 61 | 0.220 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 42 | 0.220 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 125 | 0.220 |
Why?
|
| Female | 13 | 2025 | 70607 | 0.210 |
Why?
|
| Aquaporin 4 | 1 | 2023 | 14 | 0.200 |
Why?
|
| Spin Labels | 1 | 2023 | 21 | 0.200 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 35 | 0.200 |
Why?
|
| Rituximab | 1 | 2024 | 166 | 0.200 |
Why?
|
| Oligodendroglia | 1 | 2023 | 78 | 0.200 |
Why?
|
| Racemases and Epimerases | 1 | 2022 | 12 | 0.190 |
Why?
|
| NADP | 1 | 2022 | 54 | 0.190 |
Why?
|
| NAD | 1 | 2022 | 52 | 0.190 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2023 | 149 | 0.190 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1176 | 0.180 |
Why?
|
| Pyridostigmine Bromide | 1 | 2021 | 12 | 0.180 |
Why?
|
| Seizures | 2 | 2023 | 895 | 0.170 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 48 | 0.170 |
Why?
|
| Movement Disorders | 1 | 2023 | 223 | 0.170 |
Why?
|
| Alleles | 1 | 2025 | 1684 | 0.170 |
Why?
|
| Mutation, Missense | 1 | 2025 | 937 | 0.170 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 498 | 0.170 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 139 | 0.170 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2017 | 43 | 0.170 |
Why?
|
| Prednisone | 1 | 2021 | 252 | 0.160 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 466 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 803 | 0.160 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 98 | 0.160 |
Why?
|
| Blood Pressure | 1 | 2025 | 1394 | 0.160 |
Why?
|
| Critical Care | 1 | 2025 | 686 | 0.160 |
Why?
|
| Electroencephalography | 1 | 2024 | 908 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2021 | 180 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2025 | 700 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2025 | 1579 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2021 | 415 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2021 | 387 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1830 | 0.140 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 430 | 0.140 |
Why?
|
| Age Factors | 2 | 2021 | 2920 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1386 | 0.130 |
Why?
|
| Phenotype | 2 | 2023 | 4538 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 672 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 411 | 0.130 |
Why?
|
| Intellectual Disability | 1 | 2023 | 1093 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 378 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 2551 | 0.120 |
Why?
|
| Receptors, AMPA | 1 | 2015 | 50 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 1993 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3358 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 382 | 0.110 |
Why?
|
| Pregnanolone | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2014 | 4 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2222 | 0.110 |
Why?
|
| Conditioning, Operant | 1 | 2014 | 17 | 0.110 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2014 | 14 | 0.110 |
Why?
|
| Alcohols | 1 | 2014 | 17 | 0.110 |
Why?
|
| Central Nervous System Depressants | 1 | 2014 | 22 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 501 | 0.110 |
Why?
|
| Ventral Tegmental Area | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cross Infection | 1 | 2017 | 343 | 0.110 |
Why?
|
| Nucleus Accumbens | 1 | 2014 | 56 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2025 | 6526 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2023 | 2487 | 0.100 |
Why?
|
| Bacteria | 1 | 2017 | 522 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12996 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 359 | 0.100 |
Why?
|
| Adult | 3 | 2024 | 31506 | 0.090 |
Why?
|
| Infant | 3 | 2021 | 13032 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 3198 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2025 | 1078 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3415 | 0.060 |
Why?
|
| Aged | 3 | 2025 | 21394 | 0.060 |
Why?
|
| Plasmapheresis | 1 | 2025 | 33 | 0.060 |
Why?
|
| Influenza B virus | 1 | 2025 | 100 | 0.060 |
Why?
|
| Self Administration | 2 | 2015 | 52 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2025 | 198 | 0.060 |
Why?
|
| Rats, Long-Evans | 2 | 2015 | 102 | 0.060 |
Why?
|
| Middle Aged | 3 | 2025 | 28893 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2025 | 194 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2025 | 152 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5394 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2025 | 308 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 626 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 155 | 0.050 |
Why?
|
| Gait | 1 | 2023 | 140 | 0.050 |
Why?
|
| Muscle Hypotonia | 1 | 2023 | 199 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1493 | 0.040 |
Why?
|
| Nervous System | 1 | 2021 | 127 | 0.040 |
Why?
|
| Cell Line | 1 | 2025 | 2724 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2025 | 1966 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 428 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1379 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 2703 | 0.040 |
Why?
|
| United States | 2 | 2025 | 11619 | 0.040 |
Why?
|
| Mass Screening | 1 | 2025 | 830 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2023 | 749 | 0.040 |
Why?
|
| Rats | 2 | 2015 | 3606 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8535 | 0.030 |
Why?
|
| Monobactams | 1 | 2017 | 7 | 0.030 |
Why?
|
| Quinolones | 1 | 2017 | 58 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2017 | 69 | 0.030 |
Why?
|
| Carbapenems | 1 | 2017 | 43 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2024 | 893 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2017 | 139 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2850 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 438 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 324 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3373 | 0.030 |
Why?
|
| Xanthenes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Discrimination Learning | 1 | 2015 | 23 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 329 | 0.030 |
Why?
|
| Animals | 4 | 2022 | 34908 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2015 | 40 | 0.030 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2014 | 6 | 0.030 |
Why?
|
| Phenylacetates | 1 | 2014 | 22 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 60 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 96 | 0.030 |
Why?
|
| Benzamides | 1 | 2014 | 124 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 329 | 0.030 |
Why?
|
| Glycine | 1 | 2014 | 162 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3852 | 0.020 |
Why?
|
| Amino Acids | 1 | 2015 | 626 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2014 | 330 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 521 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 6435 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9929 | 0.020 |
Why?
|